StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Core SG&A expense by Quarter

Core SG&A expense ($M) ($M)

QuarterlyAnnual

AstraZeneca Core SG&A expense: -$4,050M in Q2 2026, up 6.5% from a year earlier.

Latest, Q2 2026
-4,050
Period ended Jun 30, 2026
Change on a year earlier
+6.5%
-3,802 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

“|| SG&A expense | | (5,651) | | | 72 | | | 1,183 | | 346 | | (4,050) | 7 | 4”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Reported-to-Core Reconciliation.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore SG&A expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-4,050+6.5%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-3,859+11.6%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-4,453+4.2%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-3,822+6.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-3,802+1.8%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-3,457+1.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-4,275+6.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-3,605+7.5%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-3,735+13.3%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-3,413+11.8%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-4,034+12.6%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-3,355+6.2%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-3,296–Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-3,054+3.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-3,583+6.4%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-3,160+10.3%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up core SG&A expense

Cite this data

StockData. (2026). AstraZeneca Core SG&A expense ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-sga

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.